| Article Access Statistics|
| Viewed||1685 |
| Printed||113 |
| Emailed||2 |
| PDF Downloaded||141 |
| Comments ||[Add] |
Click on image for details.
| RESEARCH PAPER
|Year : 1997 | Volume
| Issue : 4 | Page : 250-254
Biochemical and physiological alterations following short term exposure to fluvalinate ľA synthetic pyrethroid
SK Garg, Shah MA Ayub, KM Garg, MM Farooqui, M Sabir
Objectives: To investigate the effect of fluvalinate on certain haematological and blood-biochemical analytes in rats.
Methods: Acute toxicity study was done on 4 groups each of 4 male and 4 female rats by administering fluvalinate in doses of 62.5, 125, 250 and 500 mg/kg, orally. Animals were observed for signs of toxicity upto 72 h; rectal temperature recorded and LD50 values determined. For sub-acute toxicity study 4 groups of female rats were used. Group I served as control and the remaining groups received fluvalinate at the dose of 17.5, 35.0 and 70.0 mg/kg/day for 21 days. Blood collected on day 22 and animals sacrificed. The following parameters were studied: (a) Biochemical assays - alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, blood urea nitrogen (BUN), cholesterol, glucose, total proteins and albumin concentrations; (b) Haematological parameters - haemoglobin (Hb), total erythrocyte count (TEC), total leucocyte count (TLC), differential leucocyte count (DLC) and absolute leucocyte count (ALC); and (c) Relative organ weights - relative organ weights of liver, kidneys, spleen and adrenals were calculated. In another set of experiment, 4 groups of female rats were administered fluvalinate (0.0, 17.5, 35, 70 mg/kg/day, orally) for 15 days to study its effect on pentobarbital-induced hypnosis and hepatic proteins.
Results: Oral LD50 values of fluvalinate in male and female rats were found to be 293 and 280 mg/kg, respectively. The gross signs of acute intoxication included hyperactivity, incoordination. ataxia. clonic convulsions, profuse sweating, salivation, piloerection and hypothermia. At terminal stage, the animals exhibited dyspnoea and death. In sub-acute studies, fluvalinate @ 17.5-70 mg/kg/day, orally for 21 days did not exert any gross behavioural changes nor significantly alter the haematological profiles. However, it (35 and 70 mg/kg/day) produced marginal to significant (P<0.05-0.01) increase in AST activity, BUN and glucose concentrations, relative liver and adrenal weights, pentobarbital hypnosis and total liver proteins; significant (P<0.05) reduction in estrogen (E2) levels without altering the ALT activity, cholesterol, total proteins and albumin concentrations, progesterone (P4) levels and relative weights of kidneys and spleen.
Conclusion: These results reveal fluvalinate to be moderately toxic compound and, seemingly, have the potential to cause chemical injury to liver and kidneys.
S K Garg
Source of Support: None, Conflict of Interest: None